Specify a stock or a cryptocurrency in the search bar to get a summary
Yunkang Group Ltd
2325Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction, and screening tests. In addition, the company offers routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. Further, it provides diagnostic testing services for financial institutions and insurance companies, including personalized diagnostic testing, medical report consultation, and hospital referral services; information technology, medical logistics, and medical equipment procurement; and healthcare technology development. The company provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China. Address: No. 9 Yayingshi Road, Guangzhou, China
Analytics
WallStreet Target Price
102.13 HKDP/E ratio
–Dividend Yield
0.25 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 2325
Dividend Analytics 2325
Dividend growth over 5 years
–Continuous growth
1 yearPayout Ratio 5 years average
-53 %Dividend History 2325
Stock Valuation 2325
Financials 2325
Results | 2019 | Dynamics |